Skip to main content

3 Reasons DOX is Risky and 1 Stock to Buy Instead

DOX Cover Image

Over the past six months, Amdocs’s shares (currently trading at $69.75) have posted a disappointing 19.8% loss, well below the S&P 500’s 7.6% gain. This might have investors contemplating their next move.

Is there a buying opportunity in Amdocs, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free.

Why Is Amdocs Not Exciting?

Even though the stock has become cheaper, we're cautious about Amdocs. Here are three reasons we avoid DOX and a stock we'd rather own.

1. Long-Term Revenue Growth Disappoints

Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Amdocs grew its sales at a sluggish 1.7% compounded annual growth rate. This fell short of our benchmarks.

Amdocs Quarterly Revenue

2. Projected Revenue Growth Is Slim

Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.

Over the next 12 months, sell-side analysts expect Amdocs’s revenue to rise by 3.2%. Although this projection indicates its newer products and services will catalyze better top-line performance, it is still below the sector average.

3. Recent EPS Growth Below Our Standards

Although long-term earnings trends give us the big picture, we like to analyze EPS over a shorter period to see if we are missing a change in the business.

Amdocs’s EPS grew at an unimpressive 8.9% compounded annual growth rate over the last two years. On the bright side, this performance was higher than its 3.8% annualized revenue declines and tells us management adapted its cost structure in response to a challenging demand environment.

Amdocs Trailing 12-Month EPS (Non-GAAP)

Final Judgment

Amdocs’s business quality ultimately falls short of our standards. Following the recent decline, the stock trades at 9.3× forward P/E (or $69.75 per share). While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We're fairly confident there are better investments elsewhere. We’d suggest looking at an all-weather company that owns household favorite Taco Bell.

High-Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.86
+0.00 (0.00%)
AAPL  260.58
+0.00 (0.00%)
AMD  203.37
+0.00 (0.00%)
BAC  52.77
+0.00 (0.00%)
GOOG  303.56
+0.00 (0.00%)
META  644.78
+0.00 (0.00%)
MSFT  398.46
+0.00 (0.00%)
NVDA  187.90
+0.00 (0.00%)
ORCL  156.54
+0.00 (0.00%)
TSLA  411.71
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.